- Home
- BIVI vs APM Comparison
BIVI vs APM Comparison
Compare BIVI & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIVI | APM |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 8.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BIVI | APM |
|---|---|---|
| Price | $1.09 | $0.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 95.9K | 74.1K |
| Earning Date | 02-09-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $0.69 |
| 52 Week High | $20.40 | $4.47 |
Technical Indicators
Market Signals| Indicator | BIVI | APM |
|---|---|---|
| Relative Strength Index (RSI) | 35.44 | 30.31 |
| Support Level | $1.11 | $0.80 |
| Resistance Level | $1.29 | $0.92 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 0.27 |
Price Performance
Historical ComparisonAbout BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.